ArticleCell & bioscience2025
Enriched environment inhibits GLT-1 ubiquitination by downregulating SMURF1 to attenuate ischemic brain injury induced excitotoxicity.
Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundExcitotoxicity induced by glutamate contributes significantly to ischemic brain injury. The role of enriched environment (EE) in promoting neurological recovery post-stroke is well-established, yet its impact on excitotoxicity remains unclear. This study aimed to elucidate the mechanisms through which EE modulates excitotoxicity in ischemic brain injury using in vivo and in vitro experiments.
resultsEE exposure effectively reduced ischemic brain injury and glutamate-induced excitotoxicity in middle cerebral artery occlusion (MCAO) rat models. Notably, EE led to upregulated expression of GLT-1, which enhanced glutamate uptake by astrocytes and mitigated cytotoxicity and neuronal death induced by oxygen-glucose deprivation/reperfusion (OGD/R). Furthermore, EE suppressed the upregulation of SMURF1, which interacted with GLT-1 to facilitate its ubiquitin-mediated degradation and downregulate GLT-1 expression. Additionally, EE enhanced m6A modification of SMURF1, promoting YTHDF2-mediated mRNA decay and reducing SMURF1 expression. Knockdown of SMURF1 boosted GLT-1 expression, improving glutamate uptake and alleviating neuronal injury and death caused by OGD/R. Conversely, overexpression of SMURF1 or knockdown of GLT-1 attenuated the neuroprotective effects of EE against excitotoxicity in MCAO rats.
conclusionEE mitigates excitotoxicity in ischemic brain injury by inhibiting SMURF1 expression through m6A modification-YTHDF2-dependent pathways, thereby suppressing GLT-1 ubiquitin-mediated degradation and enhancing glutamate uptake.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.